This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Irinotecan

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Irinotecan inhibits topoisomerase-1 which catalyses the breaking and rejoining of DNA strands.

Irinotecan is licensed for first-line use in patients with advanced colorectal cancer, in combination with fluorouracil and folinic acid, and as second-line monotherapy when fluorouracil-based therapy has failed (1)

A regime of 5-fluorouracil and leucovirin and Irinotecan has been shown to be beneficial compared to a regime without Irinotecan. There was an objective response in 39% vs 21%, a longer time before tumour progression 7 months vs 4 months and a longer median survival 15 months vs 13 months (2).

Adverse effects include:

  • can occur during or soon after irinotecan infusion
    • include cholinergic symptoms (e.g. flushing, diarrhoea, abdominal cramps, hypotension), which can be prevented by prophylactic subcutaneous atropine, and nausea and vomiting (generally prevented by anti-emetics)
  • possible potentially serious late effects include delayed diarrhoea (typically about 5 days after infusion) and neutropenia (after 5-10 days)

The summary of product characteristics should be consulted before prescribing this drug.

Reference:

  1. Drugs and Therapeutics Bulletin (2002), 40(7), 50-52.
  2. Editorial NEJM (2000), 343, 963-964

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.